Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07368270 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL: Anti-PD1 armored CD19 CAR-T cells

Sponsor

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.